Darholding Portfolio Company to List on LSE

Monday, October 16, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

BUDAPEST, October 16, 2017 /PRNewswire/ --

Darholding is pleased to announce that one of its portfolio companies,

Nuformix, will list on the London Stock Exchange via a reverse takeover of Levrett PLC. Darholding was one of the founders, along with other private and institutional shareholders, in Nuformix, a company with proprietary co-crystallization technologies.
Based in Cambridge, UK, Nuformix was founded in 2009 to unlock the therapeutic potential of approved drugs with lead programs in oncology supportive care and fibrosis. After successful early studies Nuformix sought a strategic partner and investor to take its programs further, which it found in the form of Levrett plc. Under the terms of the reverse takeover, announced on 15 September 2017, Levrett and Nuformix will merge and at the same time investors will place GBP 2.4 million of new capital in support of further developing the clinical studies. 

Darholding is a Budapest based upstream innovation incubating organization with interests in scientific research in pharmaceuticals, agrochemicals, fine chemicals, flavors and fragrances, laboratory instrumentation and chemistry development in Space. It operates globally through a network of companies who are all pioneers in their chosen field.

Contact: Gergely Darvas, Investment Director, Darholding Ltd [email protected]    +36-20-9494-300   

SOURCE Darholding Ltd



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store